1. [1] S. B. Whittle, V. Smith, E. Doherty, S. Zhao, S. McCarty, and P. E. Zage, “Overview and recent advances in the treatment of neuroblastoma,” Expert Rev. Anticancer Ther., vol. 17, no. 4, pp. 369–386, 2017.
2. [2] P. D. Q. P. T. E. Board, “Neuroblastoma Treatment (PDQ®),” in PDQ Cancer Information Summaries, National Cancer Institute (US), 2020.
3. [3] G. M. Brodeur, “Neuroblastoma: biological insights into a clinical enigma,” Nat. Rev. Cancer, vol. 3, no. 3, pp. 203–216, 2003, doi: 10.1038/nrc1014.
4. [4] H. Bassiri, A. Benavides, M. Haber, S. K. Gilmour, M. D. Norris, and M. D. Hogarty, “Translational development of difluoromethylornithine (DFMO) for the treatment of neuroblastoma,” Transl. Pediatr., vol. 4, no. 3, p. 226, 2015.
5. [5] R. G. G. Russell, “Bisphosphonates: mode of action and pharmacology,” Pediatrics, vol. 119, no. Supplement 2, pp. S150--S162, 2007.